Thursday, October 15, 2026
Via News Knowledge File

Berkshire Hathaway

organization80% conf.·synced Oct 14, 2026

Parent company of Jazzwares

60
sourced metrics
869
relationships
20
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week Low
465.40USD
Oct 13, 2026reference only
Price 52 Week High
529.42USD
Oct 13, 2026reference only
Market Cap
490125594USD
Oct 13, 2026reference only
Stock Return Ytd
4.8%
Oct 13, 2026reference only
Stock Price
520.59USD
Oct 13, 2026reference only
Net Income
25667000000.0USD
Jun 30, 2026reference only
Total Liabilities
512894000000.0USD
Jun 30, 2026reference only
Stockholders Equity
747910000000.0USD
Jun 30, 2026reference only
Total Assets
1263071000000.0USD
Jun 30, 2026reference only
Revenue
101808000000.0USD
Jun 30, 2026reference only
Capex
4986000000.0USD
Mar 31, 2026reference only
Operating Cash Flow
10438000000.0USD
Mar 31, 2026reference only

Stated objectives

Divest 325 million shares of Kraft Heinz

source
target: 325 million shares stated

Build upon trillion-dollar valuation under new leadership

source
stated

Continue collecting growing Coca-Cola quarterly dividend checks expected to increase over time

source
stated

Build cash reserves to be prepared to act when opportunities arise during market disruptions

source
stated

Generate market-beating returns with $380 billion cash pile under new CEO Greg Abel

source
stated

Maintain consolidated cash, cash equivalents, and Treasury bills above $30 billion threshold before conducting share repurchases

source
target: 30000000000 stated

Avoid investments that undermine the fabric of society or could jeopardize Berkshire's reputation

source
stated

Retain earnings as long as more than one dollar of market value is likely to be created per dollar retained rather than paying dividends

source
stated

Maintain concentrated portfolio in a small group of dividend-paying companies

source
stated

Maintain concentrated portfolio in small group of dividend-paying companies

source
stated

Relationship graph · 869 connections

Invested in
269
Employs
230
Owns
75
board member of
64
subsidiary of
43
Covered by
39
founded
37
employed by
24

Where sources disagree

We surface conflicts between sources rather than hiding them.

value conflictunresolved

Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com